Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adherens junction 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
4 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
5 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
6 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
7 African trypanosomiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
13 Alcoholic liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
14 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
15 Allograft rejection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
16 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
17 Alzheimer disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
18 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
19 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
20 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
21 Amoebiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
22 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
23 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
24 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
25 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
26 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
27 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
28 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
29 Antifolate resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
30 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
31 Antigen processing and presentation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
32 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
33 Apoptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
34 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
35 Asthma 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
36 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
37 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
38 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
39 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
40 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
41 Bladder cancer 💬
 1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
42 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
43 Bladder cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
44 Breast cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
45 Breast cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
46 Breast cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
47 Breast cancer 💬
 2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
48 C-type lectin receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
49 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
50 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
51 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
52 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
53 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
54 Calcium signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
55 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
56 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
57 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
58 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
59 Calcium signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
60 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
61 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
62 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
63 cAMP signaling pathway 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
64 Cellular senescence 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
65 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
66 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
67 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
68 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
69 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
70 cGMP-PKG signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
71 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
72 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
73 Chagas disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
74 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
75 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
76 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
77 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
78 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
79 Chemical carcinogenesis - receptor activation 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
80 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
81 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
82 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
83 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
84 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
85 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
86 Complement and coagulation cascades 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
87 Coronavirus disease - COVID-19 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
88 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
89 Cytokine-cytokine receptor interaction 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
90 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
91 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
92 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
93 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
94 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
95 Dilated cardiomyopathy 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
96 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
97 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
98 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
99 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
100 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
101 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
102 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
103 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
104 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
105 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
106 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
107 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
108 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
109 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
110 Epstein-Barr virus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
111 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
112 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
113 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
114 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
115 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
116 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
117 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
118 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
119 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
120 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
121 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
122 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
123 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
124 Focal adhesion 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
125 FoxO signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
126 Gap junction 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
127 Gap junction 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
128 Gap junction 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
129 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
130 Gastric acid secretion 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
131 Gastric cancer 💬
 1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
132 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
133 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
134 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
135 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
136 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
137 GnRH secretion 💬
 1件: ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
138 GnRH secretion 💬
 1件: ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
139 GnRH secretion 💬
 1件: ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
140 Graft-versus-host disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
141 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
142 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
143 Hematopoietic cell lineage 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
144 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
145 Hepatitis B 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
146 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
147 Hepatitis C 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
148 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
149 Herpes simplex virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
150 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
151 HIF-1 signaling pathway 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
152 HIF-1 signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
153 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
154 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
155 Human cytomegalovirus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
156 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
157 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
158 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
159 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
160 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
161 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
162 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
163 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
164 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
165 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
166 Human papillomavirus infection 💬
 1件: PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
167 Human papillomavirus infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
168 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
169 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
170 Human papillomavirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
171 Human T-cell leukemia virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
172 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
173 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
174 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
175 Hypertrophic cardiomyopathy 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
176 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
177 IL-17 signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
178 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
179 Inflammatory bowel disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
180 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
181 Influenza A 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
182 Influenza A 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
183 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
184 Insulin resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
185 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
186 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
187 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
188 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
189 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
190 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
191 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
192 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
193 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
194 Legionellosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
195 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
196 Leishmaniasis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
197 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
198 Lipid and atherosclerosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
199 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
200 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
201 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
202 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
203 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
204 Malaria 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
205 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
206 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
207 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
208 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
209 MAPK signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
210 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
211 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
212 MAPK signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
213 Measles 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
214 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
215 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
216 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
217 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
218 mTOR signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
219 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
220 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
221 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
222 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
223 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
224 Necroptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
225 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
226 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
227 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
228 Neuroactive ligand-receptor interaction 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
229 Neuroactive ligand-receptor interaction 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
230 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
231 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
232 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
233 NOD-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
234 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
235 Non-alcoholic fatty liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
236 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
237 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
238 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
239 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
240 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
241 Osteoclast differentiation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
242 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
243 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
244 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
245 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
246 Pancreatic cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
247 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
248 Pathogenic Escherichia coli infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
249 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
250 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
251 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
252 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
253 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
254 Pathways in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
255 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
256 Pathways in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
257 Pathways of neurodegeneration - multiple diseases 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
258 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
259 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
260 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
261 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
262 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
263 Pertussis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
264 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
265 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
266 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
267 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
268 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
269 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
270 Prion disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
271 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
272 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
273 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
274 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
275 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
276 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
277 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
278 Proteoglycans in cancer 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
279 Proteoglycans in cancer 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
280 Proteoglycans in cancer 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
281 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
282 Proteoglycans in cancer 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
283 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
284 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
285 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
286 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
287 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
288 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
289 Ras signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
290 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
291 Ras signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
292 Regulation of actin cytoskeleton 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
293 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
294 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
295 Regulation of lipolysis in adipocytes 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
296 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
297 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
298 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
299 Renal cell carcinoma 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
300 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
301 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
302 Renin secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
303 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
304 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
305 Rheumatoid arthritis 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
306 Rheumatoid arthritis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
307 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
308 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
309 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
310 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
311 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
312 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
313 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
314 Salivary secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
315 Salmonella infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
316 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
317 Shigellosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
318 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
319 Signaling pathways regulating pluripotency of stem cells 💬
 3件: FGFR1, FGFR2, FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
320 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
321 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
322 Staphylococcus aureus infection 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
323 Systemic lupus erythematosus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
324 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
325 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
326 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
327 T cell receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
328 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
329 TGF-beta signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
330 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
331 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
332 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
333 Th17 cell differentiation 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
334 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
335 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
336 Thermogenesis 💬
 1件: ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
337 Thermogenesis 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
338 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
339 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
340 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
341 TNF signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
342 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
343 Toll-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
344 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
345 Toxoplasmosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
346 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
347 Transcriptional misregulation in cancer 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
348 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
349 Tuberculosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
350 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
351 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
352 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
353 Type I diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
354 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
355 Type II diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
356 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
357 VEGF signaling pathway 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
358 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
359 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
360 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
361 VEGF signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
362 Viral protein interaction with cytokine and cytokine receptor 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
363 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
364 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
365 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
366 Yersinia infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
367 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ